๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

The future of HR management: Research needs and directions

โœ Scribed by Mark V. Roehling; Wendy R. Boswell; Paula Caligiuri; Daniel Feldman; Mary E. Graham; James P. Guthrie; Motohiro Morishima; Judith W. Tansky


Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
103 KB
Volume
44
Category
Article
ISSN
0090-4848

No coin nor oath required. For personal study only.

โœฆ Synopsis


Abstract

The contributors to this special issue provide unique perspectives and insights about the future of human resource management, and many of their ideas present opportunities for future research. Our intent is to focus on identifying and briefly discussing the key needs and directions suggested by these articles. The discussion is organized around four general themes: the HR function and its impact, the roles of HR professionals, the value of HR competencies, and the HR implications of globalization. ยฉ 2005 Wiley Periodicals, Inc.


๐Ÿ“œ SIMILAR VOLUMES


Future research in group support systems
โœ JAY F. NUNAMAKER; JR ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 889 KB

Group support systems (GSS) represent one of the real success stories of research by the MIS academic community. There is no doubt that GSS academic research has had an impact on practice in the MIS field. This paper discusses the future of GSS research in terms of what is needed, some important res

What the future holds for ectodermal dys
โœ Harold C. Slavkin ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 71 KB ๐Ÿ‘ 1 views

## Abstract A contrarian view suggests that the ectodermal dysplasias, including more than 200 different disorders, represent clinical variability and molecular heterogeneity as well as complex multigene heritable conditions often characterized by dysmorphogenesis of derivatives of embryonic ectode

New applications of gemcitabine and futu
โœ James L. Abbruzzese ๐Ÿ“‚ Article ๐Ÿ“… 2002 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 277 KB ๐Ÿ‘ 1 views

Gemcitabine has been reported to be an active agent in pancreatic cancer. Recent applications have included the use of a fixed-dose rate regimen in patients with advanced pancreatic cancer based on the observation that deoxycytidine kinase is saturated at the plasma gemcitabine concentrations achiev